To explore the role of N6-methyladenosine (m6A) RNA methylation in sepsis-induced cardiomyopathy (SICM), emphasizing its significance in cardiac dysfunction, and identify therapeutic opportunities and translational gaps.
Key Findings:
Sepsis-induced cardiomyopathy occurs in up to 60% of sepsis patients and is linked to increased mortality, highlighting the need for targeted therapies.
m6A modification is crucial in regulating cardiac transcript destiny through writers, erasers, and readers, influencing potential therapeutic strategies.
The eraser FTO shows consistent cardioprotective effects, while ALKBH5 exacerbates pyroptotic injury, indicating the need for careful consideration of m6A regulators in therapy.
m6A pathways converge on the SLC7A11/GPX4/NRF2 antioxidant network, highlighting ferroptosis-related regulation as a potential therapeutic target.
Interpretation:
The findings suggest that m6A RNA methylation plays a significant role in the pathophysiology of SICM, with specific regulators influencing cardiac injury and recovery mechanisms, warranting further investigation.
Limitations:
Heavy reliance on lipopolysaccharide-based models, which may not fully represent human sepsis.
Limited use of primary cardiomyocytes and cardiac-specific genetic tools, restricting the applicability of findings.
Lack of human validation for findings, emphasizing the need for clinical studies.
Conclusion:
Addressing the identified translational gaps is crucial for the development of m6A-targeted therapies in SICM, underscoring the urgency of this research.
